Freshfields advises Cheplapharm on the acquisition of a product portfolio from Astellas
The international law firm Freshfields Bruckhaus Deringer ('Freshfields') has advised Cheplapharm Arzneimittel GmbH ('Cheplapharm') on an agreement with Astellas Pharma Inc., a Japan based pharmaceutical company, to purchase products rights for five products in certain countries (Europe, Russia, Commonwealth of Independent States, Asia) through an asset deal.
Cheplapharm is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. It has been one of the fastest-growing pharmaceutical companies in Europe.
Freshfields advised on all legal cross-border aspects of the asset purchase agreement. The Freshfields core team comprised partners Jochen Dieselhorst and Lars Meyer as well as Johannes Kater, Elisabeth Wulf and Christoph Becherer (all Corporate); partner Christian Ruoff and Andrea Strackerjan advised on tax topics.
Cheplapharm's inhouse legal team included Legal Counsel Dr. Jan Klumb and Junior Legal Counsel Anees Ahmed.
Notes to editors
About Freshfields Bruckhaus Deringer LLP
Freshfields Bruckhaus Deringer LLP is a global law firm with a long track record of successfully advising the world's leading national and multinational corporations and financial institutions on ground-breaking and business-critical challenges. Our team of more than 2,800 lawyers and other legal professionals delivers global results from our 28 offices worldwide. Our commitment, local and multinational expertise and business know-how means our clients can rely on us when it matters most.